The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV infection with antiretroviral therapy (ART). The scope includes guidance on the initiation of ART in those previously naïve to therapy, support of patients on treatment, management of patients experiencing virological failure and recommendations in specific patient populations where other factors need to be taken into consideration.
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection and at community advocates responsible for promoting the best interests and care of HIV positive adults. They should be read in conjunction with other published BHIVA guidelines.
BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 (updated November 2013)
Appendices for these guidelines
Download Appendices 1 and 2
Download Appendix 3.1
Download Appendix 3.2
Download Appendix 3.3
Download Appendix 4
Download the comments received by the BHIVA Secretariat during the web consultation process
Presentation on these guidelines is available to download and use to facilitate dissemination and implementation of the BHIVA guidance.
Download the PDF
Download the Powerpoint Presentation
Dr Ian Williams, Dr Duncan Churchill, Prof Jane Anderson, Dr Marta Boffito, Prof Mark Bower, Mr Gus Cairns, Dr Simon Edwards, Dr Sarah Fidler, Dr Martin Fisher, Dr Andrew Freedman, Prof Anna Maria Geretti, Dr Yvonne Gilleece, Prof Rob Horne, Prof Margaret Johnson, Prof Saye Khoo, Prof Clifford Leen, Mr Neal Marshall, Dr Mark Nelson, Dr Chloe Orkin, Dr Nicholas Paton, Prof Andrew Phillips, Dr Frank Post, Dr Anton Pozniak, Prof Caroline Sabin, Mr Roy Trevelion, Dr Andrew Ustianowski, Dr John Walsh, Dr Laura Waters, Dr Edmund Wilkins, Dr Alan Winston, Dr Mike Youle
Guidelines updates and date of next review
The guidelines will be fully updated and revised in 2014. However, the Writing Group will continue to meet regularly to consider new information from high-quality studies an publish amendments and addendums to the current recommendations before the full revision date where this is thought to be clinically important to ensure continued best practice.
HIV Medicine (2014), 15 (Suppl. 1), 1–85.